Xueqian Gong
Executive Director, Translational Sciences, Lilly Oncology Eli Lilly & Co.
Dr. Xueqian Gong is Associate Vice President of Translational Sciences at Lilly Oncology and a leader in translational oncology. With two decades of experience in cancer drug development, he has played key roles in advancing multiple oncology programs, including abemaciclib, imlunestrant, olomorasib, and Lilly’s ADC portfolio, from translational strategy through clinical development. Dr. Gong has authored numerous scientific publications and patents and holds a PhD in Molecular Genetics and Genomics from the Chinese Academy of Sciences.
Seminars
Monday 12th October 2026
Exploring Sofetabart Mipitecan Enhanced Anti-Tumor Activity in Combination with SoC Therapies in Ovarian Cancer Models to Support Clinical Development
10:00 am
- Combining Sofe-M with SoC agents across in vitro and in vivo ovarian cancer models to show superior, well tolerated anti-tumor activity, including enhanced cytotoxicity with olaparib in HRD models
- Sofe-M alone or with bevacizumab was highly effective in induction and subsequent treatment in tumor models with moderate SoC responses
- Contextualizing preclinical findings to support clinical development of Sofe-M in combination with other approved therapeutic agents for ovarian cancer
